UBS analyst Karl Keirstead lowered the firm’s price target on DocuSign to $52 from $65 and keeps a Neutral rating on the shares ahead of its Q3 results this week. The analyst is citing the risk of a guide-down in January quarter outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DOCU: